Table 3.
Table 3 Weight gain liability of psychotropic agents used in SMI (see 45, 63,64,65,87, 95, 99, 104, 120, 121,122,123,124,125,126,127,128,129,130
| Drug class | Weight loss | Relatively weight neutral | Weight gain |
| Antidepressants | Bupropion | Citalopram | Substantial |
| Fluoxetine | Duloxetine | Amitriptyline | |
| Escitalopram | Imipramine | ||
| Nefazodone | Mirtazapine | ||
| Sertraline | |||
| Venlafaxine | Intermediate | ||
| Nortriptyline | |||
| Paroxetine | |||
| Anticonvulsants/ | Topiramate | Lamotrigine | Substantial |
| Mood stabilizers | Zonisamide | Oxcarbazepine | Lithium |
| Valproate | |||
| Intermediate | |||
| Carbamazepine | |||
| Gabapentin | |||
| Antipsychotics | Aripiprazole (in pre-treated individuals) | Amisulpride | Substantial |
| Molindone (in pre-treated individuals) | Aripiprazole | Chlorpromazine | |
| Ziprasidone (in pre-treated individuals) | Asenapine | Clozapine | |
| Fluphenazine | Olanzapine | ||
| Haloperidol | |||
| Lurasidone | Intermediate | ||
| Perphenazine | Iloperidone | ||
| Ziprasidone | Quetiapine | ||
| Risperidone | |||
| Thioridazine | |||
| Zotepine |